pegasys therapy

Here is what I found for Incivek or Victrelis in combo with Pegasys, Ribavirin and Simvastatin. Both PIs are contraindicated.

The other 30 patients will be randomized into comparator control arms receiving either Pegasys® or Zadaxin® (in the absence of NAP therapy) in addition to continuing Viread®.

End of February result: Hbs Ag (Quant) : 44575.47 Hbs Ag : Reactive Hbe Ag : Reactive ANTI-Hbs (Quant): < 3.0 Non-Reactive HBV DNA : 440771328 ========================================== Decided to go on Combo therapy TDF + Pegasys ========================================== Baseline result (mid of March), after baseline, start taking on medication Hbs Ag (Quant) : 44977.03 Hbs Ag : Reactive Hbe Ag : Reactive ANTI-Hbs (Quant): < 3.

is anyone else out there trying the new triple therapy w/ Incivek?

A viral relapse as you experienced frequently results in a spike in viral load. Often this will drop after some time. Therapy will lower platelet counts. That's normal. Most patients starting at 105,000 will be able to complete the treatment course even though platelets may drop below 50,000. For most liver specialists in the US 35,000 or so is the point for concern - they would likely reduce interferon dosage. You can also expect anemia and low white blood cell counts while on therapy.

This shorter treatment duration with Pegasys/Copegus will provide patients with the full benefits of therapy while reducing unnecessary drug exposure. This is good news for eligible patients as previously, all patients with genotype 2 or 3 hepatitis C (HCV) received 24 weeks of Pegasys/Copegus therapy, regardless of their baseline virus levels and response while on treatment.

MRK), known as MSD outside of the United States and Canada, reported that final results from a Phase III study of VICTRELIS™ (boceprevir), its investigational oral hepatitis C protease inhibitor, added to peginterferon alfa-2a (Pegasys®) and ribavirin therapy demonstrated significantly higher sustained virologic response (SVR)1 rates in adult patients who failed previous treatment for chronic hepatitis C virus (HCV) genotype 1 compared to a control group receiving peginterferon alfa-2a and riba

I have been on Pegasys for 13 weeks. Took my quantification but did not see much difference. There has been only 4.8% reduction but my viral load shows improvement. Hepatitis B Viral (HBV DNA, Quantitative Real Time PCR) from 4,76,172 IU/mL to 12172 IU/mL Hepatitis B Surface Antigen: 5966.72 IU/mL to 4328.60 IU/mL So my doc suggested to put me on combo therapy. He suggested that I take tenofovir along with pegasys for another 12 weeks. I am not sure if this is going to be of any help.

SVR for Pegasys plus Copegus combination therapy is 44-51% for genotype 1, and 70-82% for genotypes 2 through 6. Pegasys is a ready-made solution that is dosed at 180µg regardless of a person's weight. The FDA has also approved Pegasys for treatment of chronic hepatitis B and Pegasys plus Copegus for the treatment of people with HIV and hepatitis C coinfection.

I think i ll continue with pegasys and after completion of 1 year therapy, i should go for the vaccine engerix B

The REP 301 protocol (NCT02233075) is being conducted in 12 Caucasian patients in Moldova with HBV / HDV co-infection and involves 15 weeks of monotherapy with REP 2139-Ca, followed by 15 weeks of combination therapy with REP 2139-Ca and Pegasys™ followed by 33 weeks of consolidation therapy with Pegasys™ alone. Full details of the REP 301 trial can be found at: http://www.clinicaltrials.gov/ct2/show/NCT02233075?

GS-9256 placebo 8 Recruiting A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C Condition: Hepatitis C, Chronic Interventions: Drug: Tegobuvir (GS-9190); Drug: GS-9451; Biological: Pegasys®; Drug: Copegus®; Drug: Tegobuvir placebo; Drug: GS-9451 placebo Good luck.

The focus of this study was to evaluate the safety and efficacy of sequential peginterferon α-2a (Pegasys) therapy for chronic hepatitis B with acute exacerbation [ALT > 10 × upper limit of normal (ULN), bilirubin 10 × ULN) plus Pegasys (180 μg/kg/week, when ALT was 5–10 × ULN) for 24 weeks. Thirteen HBeAg-negative patients (Group 2) had the same protocol for 48 weeks. In both groups, entecavir was then discontinued 14 days after the initiation of Pegasys.

4 Dose Modifications If severe adverse reactions or laboratory abnormalities develop during combination PEGASYS/COPEGUS therapy, the dose should be modified until the adverse reactions abate. If intolerance persists after dose adjustment, PEGASYS/COPEGUS therapy should be discontinued. Table 3, Table 4, Table 5, and Table 6 provide guidelines for dose modifications and discontinuation of PEGASYS/COPEGUS based on laboratory abnormalities, patient’s depression status, and cardiac status.

I have done all 3 therapies, Peg-Intron,Infergen,and Pegasys(102 weeks).I could clear for 5 or 6 mths. on therapy and then it would blast me again. The Hep C has brought along Neuropathy, Cryoglobulinema, and Vasculitis. I have taken 4 infusions of Rituxin,(which is the normal dosage to begin with)),hoping to control the cryo and they are now having me take 1 infusion treatment of Rituxin, every 3 mths. So possibly the Reclast is a maintainence therapy also?

I start Triple Therapy tomorrow and I am absoluteky TERRIFIED!!! Im only 26 but have an infant and 4 year old and while medicaid is gonna pay for my meds I figure I better jump on it! Im taking the following medicines: Ribavirin 200mg tablet, INCIVEK 375mg tablet, & Pegintron Redipen 120mcg My nurse said first few shots would be rough but I read this not to be true, that they get worse and worse the further u go along!!

Patients with these conditions at baseline who cannot be effectively treated by medication should not begin Pegasys therapy. Patients who develop these conditions during treatment and cannot be controlled with medication may require discontinuation of Pegasys therapy. http://www.drugs.com/pro/pegasys.

Patients were randomized to receive standard therapy (n = 38; 48 weeks treatment) or extended therapy (n = 42; 72 weeks treatment). Extended therapy resulted in a significantly higher HBV DNA inhibition at 24 and 48 weeks after the end of treatment, a significantly higher sustained HBV DNA inhibition at the end of treatment, and a significantly lower HBsAg level at 24 and 48 weeks after the end of treatment (P < 0.05 for all comparisons).

I started Pegasys injection in June 2010 and finished the treatment in May 2011. In total , I had 48 jabs. My hair( only some parts of my head ) got thinned 4 months after I started Pegasys. Now, 1 year after I finished the treatment , the hair remains thinned and shows no sign of regrowth. I am afraid my hair will never regrow. I am just 29 and I am very self conscious about my appearance.

Pegasys therapy

Common Questions and Answers about Pegasys therapy

pegasys